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Background: The benefits of treating ANCA-associated vasculitis (AAV) in advancing age remains unclear with 1 
most published studies defining elderly as >65 years. This study aims to determine outcomes of induction 2 
immunosuppression in patients aged >75 years.  3 
 
Method: A cohort of patients aged >75 years with a diagnosis of AAV between 2006-2018 was constructed from 4 
two centres. Follow up was to two years or death. Analysis included multivariable Cox regression to compare 5 
mortality and ESRD based on receipt of induction immunosuppression therapy with either cyclophosphamide or 6 
rituximab. A systematic review of outcome studies was subsequently undertaken amongst this patient group 7 
through Pubmed, Cochrane and Embase databases from inception until 16/10/19.  8 
 
Results: 67 patients were identified. Mean age was 79 + 2.9 years and 82% (n=55) received induction 9 
immunosuppression. Following systematic review, four studies were eligible for inclusion, yielding a combined 10 
total of 290 patients inclusive of our cohort. The aggregated one year mortality irrespective of treatment was 31% 11 
(CI 25% - 36%). Within our cohort, induction immunosuppression therapy was associated with a significantly lower 12 
two-year mortality risk [HR 0.29 (95% CI 0.09 – 0.93)]. The pooled HR by meta-analysis confirmed this with a 13 
significant risk reduction for death [HR 0.31 (95% CI 0.16 - 0.57), I2=0%]. Treated patients had a lower pooled rate 14 
of ESRD, but was not statistically significant [HR 0.71 (95% CI 0.15 – 3.35)]. 15 
 
Conclusion: This meta-analysis suggests that patients >75 years with AAV do benefit from induction 16 
immunosuppression with a significant survival benefit. Age alone should not be a limiting factor when 17 

























Introduction  19 
ANCA-associated vasculitis (AAV) tends to present with rapidly progressive renal disease, carrying a significant risk 20 
of morbidity and mortality with a poorer survival probability in those patients requiring renal replacement therapy 21 
at presentation (1). Current established immunosuppressive therapies are effective with improved patient and 22 
renal survival (2, 3), but their use requires careful patient selection when balanced against the potential risks, 23 
with up to 60% of deaths in the first year resulting from adverse effects of treatment (3, 4).  24 
Advancing age is often considered to be a negative predictor for death and end stage renal disease (ESRD) when 25 
considering treatment in patients with AAV (5, 6). This is based on the outcomes of previously published 26 
observational studies and randomised control trials, most of which tended to categorise older age as greater than 27 
65 years and may not provide an accurate representation of those with advancing age (4, 6-8). Subsequently, 28 
despite being a disease that predominantly effects the elderly, as well as the most common cause of biopsy 29 
proven acute kidney injury in patients over the age of 80 years, the benefit of treating AAV in older age groups 30 
remains unclear (9-12). This study attempts to address this by evaluating treatment outcomes in patients >75 31 
years with AAV from two centres with subsequent systematic review and meta-analysis of the published 32 
literature. 33 
 
Materials & Method 34 
Participants & Study design 35 
A cohort of consecutive patients aged >75 years with a diagnosis of AAV between 2006-2018 was constructed 36 
from two centres; one in the United Kingdom (UK) and one in the United States of America. All participants had 37 
renal impairment secondary to AAV at the time of diagnosis. Those with missing data or dual positivity for both 38 
ANCA and anti-GBM antibodies were excluded. For the remaining patients, the following data was retrospectively 39 
collected from the time of diagnosis; demographics, clinical presentation, modified Charlson comorbidity index 40 
(CCI) (13, 14), histopathology, immunosuppression therapy, patient outcomes and laboratory values including 41 
ANCA specificity, serum creatinine and estimated glomerular filtration rate (eGFR). As renal and connective tissue 42 
disease were the conditions of interest in our cohort, a modified CCI that did not include these in its calculation 43 
was used. Total score could range from 0 to 32. eGFR was calculated using the Modified Diet in Renal Disease 44 
equation (15). Cause of death was attained from review of medical records and categorised as follows; infection, 45 
active vasculitis, cardiovascular disease, respiratory disease, peripheral vascular disease, cerebrovascular disease, 46 
malignancy and unknown cause.  47 
 
Patients were categorised into two groups; those who received induction therapy and those who did not. 48 
Induction therapy was defined as regimes utilising either cyclophosphamide or rituximab. The dosing regimen of 49 
intravenous cyclophosphamide adopted in both centres adjusted for renal function and patient age in accordance 50 
with recommendations made by the European vasculitis study group (16, 17). Depending on local practice, 51 
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rituximab was administered at a dose of 375mg per square meter of body surface area per week for four weeks 52 
or as 1g every two weeks for two doses. Pulsed intravenous methylprednisolone and plasma exchange were 53 
administered according to local physician discretion. The cumulative dose range of methylprednisolone was 0.5-54 
3g. Considerations for plasma exchange included dialysis dependence, serum creatinine >500 µmol/L or 55 
pulmonary haemorrhage. This retrospective cohort study received ethical approval from the UK Health Research 56 
Authority and Confidentiality Advisory Group and institutional review board at Johns Hopkins Hospital.  57 
 
Outcomes  58 
The primary outcomes were risk of ESRD, death and the composite outcome of death or ESRD within two years 59 
of follow up. ESRD was defined by continued use of renal replacement therapy at follow up. Secondary outcomes 60 
included serious adverse events and renal recovery. Serious adverse events of therapy were defined as infection 61 
requiring hospitalisation, new onset malignancy, thrombocytopenia, leukopenia, bone marrow suppression and 62 
complications of glucocorticoid therapy including new onset diabetes mellitus, osteoporosis and osteoporotic 63 
fractures. Renal recovery was defined as sufficient improvement in renal function to achieve dialysis 64 
independence. Renal histopathology was categorised according to the Berden histopathological classification 65 
system (18).  66 
 
Systematic review & study selection for meta-analysis  67 
A systematic review was undertaken to identify any studies evaluating outcomes in patients aged >75 years with 68 
AAV. Pubmed, Cochrane and Embase databases were each searched independently by two reviewers (AM & ME) 69 
from inception until 16.10.2019 using the following search strategy; “ANCA” OR "anti-neutrophil cytoplasmic 70 
antibody" OR “vasculitis” OR “PR3” OR “MPO” OR “ANCA-associated” AND “elderly” OR “old” OR "75 years" OR 71 
“geriatric” AND “ESRD” OR "end stage renal disease" OR “dialysis” OR “death” OR “survival” OR “mortality” OR 72 
"renal replacement therapy" OR “outcome”. All outcome studies on patients >75 years with AAV, inclusive of those 73 
presenting data as a subgroup analysis, were included. Case reports, editorials, letters to the editor, review 74 
articles, conference abstracts and studies not published in English were excluded from review. Eligible studies 75 
were independently screened and reviewed by two authors. In instances of disagreement, resolution by 76 
consensus was sought. The methodological quality and risk of bias of eligible studies was assessed using the 77 
Newcastle-Ottawa scale for observational studies. The protocol for this review was registered and published on 78 
PROSPERO (http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019123279). 79 
 
Two investigators independently undertook data extraction using a predefined criterion. The study characteristics 80 
extracted for inclusion in meta-analysis were as follows; year of publication, study type, sample size of participants 81 
aged >75 years, male percentage, the number of participants who received induction immunosuppression, follow 82 
up period, the rate of death and ESRD at one and two years, the rate of serious adverse events and the hazard 83 





Statistical analysis 85 
Patient characteristics were presented as mean + SD or median for continuous variables and proportions for 86 
categorical variables. A comparison between treated and untreated groups were analysed utilising t-Tests, Mann-87 
Whitney, chi- squared or Fisher exact tests where appropriate. Patient survival times were calculated from the 88 
point of diagnosis until death, two years, loss to follow up or end of study (01/12/2018). Renal survival was 89 
calculated similarly with the addition of censor for death. The risk of death, ESRD and death or ESRD were studied 90 
using univariate and multivariable cox regression models, presented as hazard ratios (HR) with 95% confidence 91 
intervals (CI). The following parameters were adjusted for in the final model; use of induction 92 
immunosuppression, gender, CCI, eGFR at the time of diagnosis and the presence of renal limited disease. Gender 93 
and co-morbidity index were selected to reflect patient characteristics. eGFR was selected an indicator of disease 94 
severity and predictor of renal outcome. Renal limited disease was selected as a predictor variable as the absence 95 
of multi-system disease may confer a survival advantage. Univariate Kaplan-Meier curves were constructed to 96 
complement the cox regression hazard models for death, ESRD and death or ESRD. The rate of serious adverse 97 
events and impact of intravenous methylprednisolone were analysed utilising t-tests, Mann-Whitney, chi-squared 98 
or Fisher exact tests where appropriate.  99 
 
The systematic review was conducted in accordance with PRISMA guidelines. A random effects meta-analysis 100 
model was used to calculate pooled HR for ESRD and death by treatment status. Study heterogeneity was 101 
evaluated using chi- square with a significance level of P<0.10 and I2 statistics. Thresholds for I2 statistics were as 102 




Study Population  105 
Follow up data was completed in 67 patients aged >75 years, of which 98.5% (n=66) had disease confirmed on 106 
renal biopsy. Descriptive baseline characteristics for this cohort according to treatment status are shown in Table 107 
1. Mean age was 79 + 2.9 years with a mean follow up period of 1.7 + 0.62 years. Renal biopsy data was available 108 
in 94% of patients (n=63) with focal disease as the most common histological subtype as defined by the Berden 109 
classification (18). Just under half of patients had renal limited disease and ANCA serology was positive in 86.6% 110 
of patients (n=58) with a predominance for MPO serotype. 111 
 
Induction immunosuppression with cyclophosphamide or Rituximab was given to the majority of patients (82%). 112 
All received concomitant oral steroids and cyclophosphamide was the most commonly used agent with a median 113 
cumulative dose of 2.73g (interquartile range 7.14–1). 3 patients failed treatment with cyclophosphamide and 114 
warranted continued therapy with rituximab.  The non-induction cohort consisted solely of patients from the UK 115 
centre. Amongst this group, three patients received alternative oral immunosuppression at the time of diagnosis; 116 
two with azathioprine and steroids, one with steroids alone. From the induction and non-induction cohorts, 44 117 
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and 9 patients were alive and dialysis independent at 6 months, respectively. Maintenance therapy amongst these 118 
patients is shown in Table 1.  119 
 120 
A total of thirty-three patients received intravenous methylprednisolone; 56.4% (n=31) vs. 16.7% (n=2) in the 121 
induction and non-induction therapy cohorts respectively. Dosing data was available in twenty-nine patients with 122 
mean dose of 2.24 + 0.8 grams across both groups. Twelve (21.8%) patients in the induction therapy cohort 123 
received plasma exchange with treatment data available in ten cases. The median number of sessions 124 
administered was five. No patients in the non-induction therapy cohort received plasma exchange. Of the 67 125 
patients in our cohort, 26 were aged >80 years with 88.5% (n=23) receiving induction immunosuppression.  126 
 
Outcomes of study population  127 
Clinical outcomes according to treatment status are outlined in Table 2. Three patients (4.5%) died within the first 128 
three months of diagnosis, of which only one received induction therapy. The overall one and two-year survival 129 
rates irrespective of treatment were 79.1% (n=53) and 76.1% (n=51) respectively. The use of induction 130 
immunosuppression was associated with a significant reduction in the risk of death [HR 0.29 (95% CI 0.09–0.93)] 131 
(Table 3). Of the 16 deaths at the end of the two-year follow up period, one confirmed case was attributable to 132 
underlying vasculitic disease. The leading cause of death in the non-induction cohort cannot be commented on 133 
due to incomplete data with an unknown cause of death in 80% (n=4) of cases. Amongst those receiving induction 134 
therapy, infection was the leading cause of death.  135 
 
Eighteen patients (26.9%) required dialysis within thirty days of their initial presentation, with no new cases of 136 
dialysis dependence beyond this point throughout the follow up period. Of these patients, 15 received induction 137 
immunosuppression, with four recovering renal function by twelve months. At the end of the two year follow up 138 
period the rate of ESRD was 20% (n=11) and 16.7% (n=2) in the induction and non-induction cohorts respectively. 139 
In multivariable cox regression analysis, renal survival was similar between the two groups [HR 1.17 (95% CI 0.25–140 
5.54)] (Table 3). A higher eGFR at the time of initial diagnosis was associated better renal survival [HR 0.75 (95% 141 
CI 0.63–0.89)] (Table 3).  142 
 143 
The therapeutic benefit of induction immunosuppression was maintained on assessing the composite outcome 144 
of death or ESRD ([HR 0.33 (95% CI 0.12–0.86)] (Table 3). Supplementary figures 1-3 depicts univariate Kaplan-145 
Meier survival curves for death, ESRD and death or ESRD by induction immunosuppression.  146 
 
On subgroup evaluation of patients >80 years, 88% (n=23) received induction immunosuppression with a 147 
mortality rate of 21.7% (n=5) and all deaths occurring within 12 months of diagnosis. Acknowledging that analysis 148 
may be limited the small sample size, use of induction immunosuppression did not confer a higher risk of death 149 
in this group upon restricting the multivariable cox regression model to those aged >80 years [HR 0.01 (95% CI 0–150 
0.84)] (supplementary Table1). No deaths or episodes of ESRD occurred within the first year in untreated patients 151 
>80 years. 152 
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No instances of death or ESRD occurred in those patients receiving rituximab. Meaningful analysis of 153 
cyclophosphamide versus rituximab as outcome predictors was limited. Twenty-eight patients (41.8%) 154 
experienced serious adverse events, comprising of 22 patients from the induction cohort and 6 from the non-155 
induction cohort. Overall, infection accounted for the majority of cases. The use of induction immunosuppression 156 
did not confer a higher risk of serious adverse events (p=0.54). Similarly, the rate of adverse events did not 157 
significantly differ between those patients who received intravenous methylprednisolone and those who did not; 158 
42.9% (n=12) vs. 57.1% (n=16) respectively (p=0.46).  159 
 
Systematic Review & Study Selection  160 
The process of study selection is outlined in supplementary Figure 4. Thirteen citations qualified for full text 161 
review. Nine were published as abstracts only and subsequently excluded. Characteristics of the four remaining 162 
eligible studies are summarised in supplementary Table 2.  163 
 
Only three studies categorised patients according to the use of immunosuppressive therapy; Bomback et al, 164 
Weiner et al and Sato et al, with an aggregated total of 175 patients receiving induction immunosuppression (19-165 
21).  The most commonly used agent was cyclophosphamide (72.6%) with the majority receiving oral therapy 166 
(59%). Statistical analysis with stratification according to the use of induction immunosuppression was 167 
undertaken by two studies; Weiner et al and Bomback et al (19, 20). The control group in Weiner et al consisted 168 
of untreated patients as well as those receiving alternative regimes such as azathioprine, methotrexate or 169 
mycophenolate. The control group in Bomback et al consisted of untreated patients only.  170 
 
Meta-analysis results  171 
With the addition of our cohort, a sample size of 290 patients aged >75 years with AAV were available for review. 172 
The one year mortality rate irrespective of treatment was 31% (CI 25%-36%). Weiner et al and Bomback et al both 173 
used multivariable cox models to analyse the hazard of death and ESRD with induction therapy. Their results in 174 
conjunction with the findings from our presented cohort were used to present the pooled HR for death and ESRD 175 
by meta-analysis in 258 patients. The use of induction immunosuppression demonstrated a significant benefit for 176 
patient survival with a pooled hazard ratio for death of 0.31 (95% CI 0.16-0.57) [I2 = 0 %] (Figure 1). Induction 177 
therapy was also associated with a lower pooled rate of ESRD, although not statistically significant [HR 0.71 (95% 178 
CI 0.15–3.35)] (supplementary Figure 5). Serious adverse events were available for two studies with a combined 179 




To date there has been limited published data guiding treatment outcomes of AAV in older populations and the 182 
potential benefit of utilising established induction immunosuppression in those aged >75 remains poorly defined. 183 
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This represents an area of increasing clinical need owing to an overall rise in the both the incident and prevalence 184 
of disease, with the former rising from 8-10/million to 13-20/million over recent years (9, 10, 22). The present 185 
study addresses this by reporting the experiences of two centres followed by a meta-analysis of published studies. 186 
In doing so we identified a clear survival benefit in patients > 75 years treated with induction immunosuppression 187 
with either Cyclophosphamide or Rituximab.   188 
Within the first twelve months of treatment, the greatest risk to patient survival is adverse effects of therapy 189 
rather than active vasculitis, with up to 60% of deaths resulting from infection (4, 8). It is considered that with 190 
increasing age, a patient’s ability to tolerate any significant immunosuppression is reduced with a higher 191 
propensity to succumb to such adverse effects. Although not by study design, recent landmark trials in the 192 
management of AAV have tended to only include patients under the age of 75 years (17, 23-25) and to date the 193 
majority of observational studies reviewing the outcome of patients with AAV have often considered older age as 194 
being greater than 65 years (2, 5-7, 26, 27). These have identified age >65 years as a poor prognostic marker for 195 
patient outcomes and in view of this, it would be anticipated that patients older than 75 years would fare even 196 
worse.  197 
In a retrospective single centre study evaluating one-year outcomes in patients over the age of 80 years, Bomback 198 
et al demonstrated that treatment can prolong dialysis free survival with a remission rate of 49% and up to 37% 199 
fewer patients reaching ESRD at one year compared to the untreated cohort (19). Although the cumulative 200 
mortality rate was 49%, with most patients dying from infection rather than underlying disease, the risk of death 201 
at one year was 17% lower in treated patients (19). While this difference was not statistically significant, follow 202 
up beyond one year identified a significantly lower risk for both ESRD and death. In a similar study, Weiner et al 203 
evaluated the two-year survival in patients over the age of 75 years in a multi-centre retrospective study (20). 204 
Their survival analysis supported that of Bomback et al, identifying superior patient survival in those given 205 
induction therapy with 36% fewer deaths and a significantly lower hazard ratio for death on multivariable analysis 206 
(20). This remained unchanged on subgroup analysis of patients who received a lower cumulative dose of 207 
cyclophosphamide.  208 
 
Within our cohort analysis, we exhibited comparable findings to previous studies with a significantly lower hazard 209 
ratio for death in treated patients. The survival benefit of induction immunosuppression persisted despite 210 
advancing age following subgroup analysis of those aged >80 years. There was no demonstrable benefit for renal 211 
survival. The burden of co-morbidity was similar between the two groups and parallel to the findings of Bomback 212 
et al, renal function at the time of diagnosis was predictive of outcomes. When considered in light of the findings 213 
of Bomback et al, the current evidence suggests that on its own advancing age >80 years should not discount 214 
patients from treatment and that despite a higher potential risk of adverse effects, certain selected elderly 215 
patients may benefit from induction immunosuppression in AAV.  216 
 
The present meta-analysis of these observational studies confirmed a clear survival advantage of induction 217 
immunosuppression over no/other oral immunosuppression in patients >75 years with AAV. Similarly, a lower 218 
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rate of ESRD with treatment was shown, although this did not reach statistical significance. In view of these 219 
findings, the safe use a reduced dose of cyclophosphamide applied in both our cohort and Wiener et al suggests 220 
that the dosing regimen described by previous studies can safely be adopted in older patients, with sufficient 221 
mitigation of risk without compromising therapeutic benefit (4, 6, 7).  222 
 
The remaining two studies of Hoganson et al and Sato et al identified on systematic review were not included in 223 
meta-analysis (21, 28). Sato et al was a comparative study evaluating treatment outcomes of AAV in patients aged 224 
>75 years against those < 75 years. In the cohort described, patients >75 years numbered ten, of which 80% did 225 
not receive induction therapy with either Cyclophosphamide or Rituximab (21). This was despite presenting with 226 
more severe vasculitic disease due to the presumption that they were more susceptible to adverse events. The 227 
implication of this selection bias is acknowledged by the authors when concluding a poorer survival rate in elderly 228 
patients. The limitation of this study design could have affected our presented pooled one year survival rate, 229 
however it did not have any implication on our subsequent meta-analysis with no stratification of outcomes by 230 
treatment status. Similarly, data from Hoganson et al was excluded from meta-analysis on the same basis. 231 
 
Despite improved patient survival with induction immunosuppression, the question remains, at what cost is this 232 
achieved. Amongst other factors, advancing age has previously been associated with a higher degree of long term 233 
damage and this patient group are potentially more frail with increased susceptibility to any potential treatment 234 
related morbidity (29). In a follow-up study of their previously reported cohort, Weiner et al set out to address 235 
this by evaluating the potential association between end organ damage and hospitalisation rates with therapy at 236 
one and two years (30). In doing so, they identified that amongst patients >75 years the use of cyclophosphamide 237 
or rituximab was actually associated with a lower rate of damage (30). As disease severity at presentation is known 238 
risk factor for permanent organ damage (29), this finding likely reflects the benefit of attenuated disease activity 239 
achieved with therapy. There was no increased rate of hospitalisation or length of stay within 12 months of 240 
treatment (30).  241 
 
The potential for treatment related damage secondary to glucocorticoids is widely accepted and reported (29, 242 
31). Although our study showed no increased risk of adverse event secondary to methylprednisolone exposure, 243 
this is likely limited by our relatively small sample size. In their more recent study, Weiner et al did identify an 244 
association between treatment related damage and fatal infections with a higher cumulative steroid exposure 245 
within the first three months of therapy. Taking this into account in conjunction with the findings of our study, it 246 
may be that future treatment strategies of AAV in advancing age would benefit more from minimising steroid 247 
exposure, as opposed to avoidance or further modification of current therapy with rituximab or reduced dose 248 
cyclophosphamide.  249 
 
The findings of our study should be considered in context of its limitations. Firstly, the lack of randomised control 250 
trials and the retrospective design of all included studies limits the level of evidence that could be derived from 251 
them. Secondly, we acknowledge that the modified CCI scores observed in our cohort were seemingly low. In a 252 
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previous small study applying a similar modified CCI to ours at diagnosis, with the exception of weighted score for 253 
age, a higher score was associated with reduced patient and renal survival. In this study, patient age ranged from 254 
18-76 years with a mean age of 53.2 + 15.63 years and mean CCI at diagnosis of 4.9 + 2.49 (14). The lower mean 255 
CCI scores observed in our cohort would indicate a less comorbid and potentially less frail population, which would 256 
favour better outcomes and should be taken into account when interpreting our cohort results. Thirdly, allocation 257 
of treatment varied in each centre based on local expertise and clinical assessment which may have imposed a 258 
significant selection bias: a factor evident by the imbalance of untreated patients between our two centres which 259 
restricted adjustment for centre effect in the final models. This likely reflects individualisation of care based on 260 
recognition of frailty and suitability of immunosuppressive therapy; an aspect of clinical assessment which is not 261 
captured by measures such as the modified Charlson comorbidity index. A potential tool that could account for 262 
this is the Clinical Frailty Scale, a frailty screening method that has recently been validated in patients with chronic 263 
kidney disease. Its incorporation in future prospective studies could help stratify this crucial aspect of clinical 264 
judgement, further guiding future immunosuppressive therapy in renal vasculitis (32). Fourthly, statistical analysis 265 
to adjust treatment outcome according to the histological pattern of disease could not be undertaken due to 266 
limited variability and small sample size. This is a factor which may have influenced treatment decisions. These 267 
limitations should be weighed the rigorous and systematic approach of this study, as well as the previously limited 268 
data guiding treatment in our defined population. 269 
 
The question of whether or not induction immunosuppression is of more harm than benefit in patients with AAV 270 
and advancing age is of increasing importance. The data presented here from our centres and pooled results from 271 
meta-analysis suggests that patients >75 years with AAV do benefit from induction immunosuppression, with a 272 
significant survival advantage within the first two years of therapy. Age alone should not be a limiting factor when 273 
considering treatment. Future trials in AAV may benefit from increasing the upper age limit at which patients are 274 
considered elderly to 75 years in order to attain more representative data.  275 
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Figure 1 – Forest plot of mortality risk in patients with ANCA-associated vasculitis aged > 75 years based on the 
use of induction immunosuppression 
 
Supplementary Figure 1 – Kaplan-Meier survival curves for the outcome of death according to the use of 
induction immunosuppression therapy. Curves reflect univariate analysis 
 
Supplementary Figure 2 – Kaplan-Meier survival curves for the outcome of end stage renal disease (ESRD) 
according to the use of induction immunosuppression therapy. Curves reflect univariate analysis 
 
Supplementary Figure 3 – Kaplan-Meier survival curves for the composite outcome of death or end stage renal 
disease (ESRD) according to the use of induction immunosuppression therapy. Curves reflect univariate analysis 
 
Supplementary Figure 4 – Flow diagram of systematic review and study selection for meta-analysis 
 
Supplementary Figure 5 – Forest plot of ESRD risk in patients with ANCA-associated vasculitis > 75 years based 
on the use of induction immunosuppression  
 
